Use of Conversation and Acoustic Signals in Measuring Depression Severity
Status: | Archived |
---|---|
Conditions: | Depression |
Therapuetic Areas: | Psychiatry / Psychology |
Healthy: | No |
Age Range: | Any |
Updated: | 7/1/2011 |
Start Date: | January 2009 |
End Date: | December 2010 |
The purpose of this study is to test a new monitoring technology that uses the sound of a
depressed person's speech to assess the severity of depression symptoms. The Vocal Social
Signals Platform (VSSP) is software that analyzes the non-verbal characteristics of a
person's speech. This study will test this software to see if it could be a useful
measurement tool for assessing depression symptoms. Participation in this study requires
coming to the research headquarters twice over a three-month period. The first visit is to
determine eligibility. Throughout the study, participants will be connected to a telephone
system five times, on which they will answer questions about their depression symptoms.
After answering questions, their voice will be recorded using a structured speech sample
that the participant will read out loud. The participant will also give an unstructured
speech sample, which will involve describing a typical day or the last movie s/he saw. The
voice samples will be analyzed and compared to the results of the depression symptom
questionnaires.
We will conduct a 24-month study that will include the test-retest reliability, criterion
validity and sensitivity to change measurements of a novel monitoring technology that might
provide an objective measure to monitor depression symptoms. There will be no randomization
to control and experimental groups as this is a reliability/validity study of a measurement
tool. In order to evaluate this technological measure for its psychometric properties, we
will recruit 60 subjects recently diagnosed with depression. We will recruit only recently
diagnosed patients to maximize the likelihood of the person improving their depressive
severity during our study. Even though subjects will be referred by their clinicians as
depressed patients we will use CES-D or Centers for Epidemiological Studies Depression Scale
to to confirm depressive symptoms in these patients. CES-D and not PHQ-9 will be the
screener. We will also recruit 20 non-depressed subjects (who will also be screened by the
CES-D). This is done to validate the ability of the VSSP to discriminate between
non-depressed individuals and individuals presenting with depressive symptomatology. The
subjects with depression will be recruited from the Boston Medical Center's (BMC) Psychiatry
Clinic as well as BMC's two primary care practices. The non-depressed individuals will be
recruited by posting ads in Boston Metropolitan area daily newspapers. We will administer
the combined TLC-VSSP to these subjects 5 times over a three month period. This means that
subjects will receive TLC-PHQ-9 during the 5-time encounters with the study. The time
interval between the five evaluation sessions will be 1, 3, 4, and 4 weeks respectively. The
first two data collection points will include test-retest reliability of TLC-PHQ9 and VSSP.
The third, fourth and fifth data collection points will include follow-up assessments to
detect change. In addition, the first and last data collections will include an evaluation
of the criterion validity of VSS through an administration of the Inventory of Depressive
Symptomatology (IDS) by a human professional (Validity). The first and last data collections
will also be used to assess the ability of VSSP, TLC-PHQ9 and their combination to detect
change in the severity of depression (as measured by the IDS). The first and last
evaluations will be conducted in the research headquarters while the intermediate
evaluations will occur over the telephone. The IDS interviews will be tape-recorded and
conducted by a researcher. Another researcher will listen to a sample of the tapes
throughout the study to assess the interviewer¿s fidelity to the IDS clinician
administration protocol for each of the 30 items and score the questionnaire independently
of the interviewer. In addition, subjects will provide both ¿structured¿ and ¿unstructured¿
voice samples in random order at each assessment point. Baseline Visit 2 Visit 3 Visit 4
Visit 5 (telephone) (telephone) (telephone) Week 0 Week 1 Week 4 Week 8 Week 12 We designed
the study with 5 data collection points in order to observe change in symptom severity
levels at intermediate points before the final assessment at visit 5. We expect the majority
of patients to be in some type of treatment, either receiving an antidepressant medication
regimen or some form of therapy or both (we will not be concerned with the specific type of
treatment). It is reported that approximately 60% of patients on antidepressant medications
respond to treatment. Thus, we anticipate certain improvement in depressive symptoms among a
substantial proportion of subjects who are taking antidepressants. We are also aware that
some of the subjects who are being treated by antidepressants may experience side-effects.
We estimate that approximately 15% of patients on antidepressants might discontinue
treatment due to significant side-effects and lack of efficacy. In addition, some subjects
may not be completely adherent to their medication and/or therapy regimens for a variety of
reasons. These factors will make it possible to explore changes in symptom severity in two
different directions of improvement and deterioration. We will collect information on these
events (being on treatment, stopping treatment, non-adherence or under adherence to
mediation taking, missing therapy sessions, etc.) by providing the subjects with a diary and
asking them to write all treatment related events in that diary. The diary will include
specific questions about possible events in treatment regimens.
We found this trial at
1
site
Boston Med Center Boston Medical Center (BMC) is a 496-bed academic medical center located in...
Click here to add this to my saved trials